Altimmune, Inc. (ALT) stock forecast and price target
Price $1.65 · data as of November 13, 2026
12-month price target
Average target$16.33
Upside / downside+892.9%
Analysts9
ConsensusStrong buy
Low $11.00Average $16.33High $26.00
Gold marker: average target · white marker: today’s price ($1.65)
Analyst ratings
Strong buy 2Buy 7Hold 1Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-0.63 | +37.2% | $0 |
| Next fiscal year ends December 31, 2027 | $-0.69 | −10.7% | $0 |
| Next quarter ends December 31, 2026 | $-0.18 | +34.1% | $0 |
| Quarter after ends March 31, 2027 | $-0.16 | +8.9% | $0 |
Consensus of the analysts covering Altimmune, updated daily.
Frequently asked questions
What is the Altimmune stock price target?
The average 12-month target from 9 analysts is $16.33, 892.9% above the current price of $1.65 Targets range from $11.00 to $26.00.
Is Altimmune a buy according to analysts?
The consensus rating is “Strong buy” (2 strong buy, 7 buy, 1 hold). Ratings are opinions, not guarantees; this is not investment advice.
How much is Altimmune expected to earn?
Analysts expect EPS of $-0.63 for the fiscal year ending December 31, 2026 and $-0.69 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.